Global Alzheimers and Parkinsons Diseases Market Research Report 2024

Alzheimers and Parkinsons Diseases Market

Alzheimer is a chronic neurodegenerative disease that usually starts slowly and gradually worsens over time. Parkinson is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.

The global Alzheimers and Parkinsons Diseases market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Alzheimers and Parkinsons Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Alzheimers and Parkinsons Diseases is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Alzheimers and Parkinsons Diseases in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Alzheimers and Parkinsons Diseases include Hoffmann-La Roche, Novartis, Pfizer, Merck, Eli Lilly, Orion Pharma, UCB, AstraZeneca and Biogen, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Alzheimers and Parkinsons Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alzheimers and Parkinsons Diseases.

Report Scope

The Alzheimers and Parkinsons Diseases market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Alzheimers and Parkinsons Diseases market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Alzheimers and Parkinsons Diseases companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Hoffmann-La Roche

Novartis

Pfizer

Merck

Eli Lilly

Orion Pharma

UCB

AstraZeneca

Biogen

Teva Pharmaceutical Industries

AbbVie

Vertical Pharmaceuticals

ALLERGAN

ACADIA Pharmaceuticals

Impax Laboratories

GE healthcare

VTV Therapeutics

Alzheimers

Parkinsons

Hospital

Clinic

Other

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Scope of Alzheimers and Parkinsons Diseases Market Report

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Alzheimers and Parkinsons Diseases companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Alzheimers and Parkinsons Diseases Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 Alzheimers

1.2.3 Parkinsons

1.3 Market by Application

1.3.1 Global Alzheimers and Parkinsons Diseases Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Alzheimers and Parkinsons Diseases Market Perspective (2019-2030)

2.2 Alzheimers and Parkinsons Diseases Growth Trends by Region

2.2.1 Global Alzheimers and Parkinsons Diseases Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Alzheimers and Parkinsons Diseases Historic Market Size by Region (2019-2024)

2.2.3 Alzheimers and Parkinsons Diseases Forecasted Market Size by Region (2025-2030)

2.3 Alzheimers and Parkinsons Diseases Market Dynamics

2.3.1 Alzheimers and Parkinsons Diseases Industry Trends

2.3.2 Alzheimers and Parkinsons Diseases Market Drivers

2.3.3 Alzheimers and Parkinsons Diseases Market Challenges

2.3.4 Alzheimers and Parkinsons Diseases Market Restraints

3.1 Global Top Alzheimers and Parkinsons Diseases Players by Revenue

3.1.1 Global Top Alzheimers and Parkinsons Diseases Players by Revenue (2019-2024)

3.1.2 Global Alzheimers and Parkinsons Diseases Revenue Market Share by Players (2019-2024)

3.2 Global Alzheimers and Parkinsons Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Alzheimers and Parkinsons Diseases Revenue

3.4 Global Alzheimers and Parkinsons Diseases Market Concentration Ratio

3.4.1 Global Alzheimers and Parkinsons Diseases Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Alzheimers and Parkinsons Diseases Revenue in 2023

3.5 Alzheimers and Parkinsons Diseases Key Players Head office and Area Served

3.6 Key Players Alzheimers and Parkinsons Diseases Product Solution and Service

3.7 Date of Enter into Alzheimers and Parkinsons Diseases Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Alzheimers and Parkinsons Diseases Historic Market Size by Type (2019-2024)

4.2 Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Type (2025-2030)

5.1 Global Alzheimers and Parkinsons Diseases Historic Market Size by Application (2019-2024)

5.2 Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Application (2025-2030)

6.1 North America Alzheimers and Parkinsons Diseases Market Size (2019-2030)

6.2 North America Alzheimers and Parkinsons Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024)

6.4 North America Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7.1 Europe Alzheimers and Parkinsons Diseases Market Size (2019-2030)

7.2 Europe Alzheimers and Parkinsons Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024)

7.4 Europe Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size (2019-2030)

8.2 Asia-Pacific Alzheimers and Parkinsons Diseases Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2019-2024)

8.4 Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Alzheimers and Parkinsons Diseases Market Size (2019-2030)

9.2 Latin America Alzheimers and Parkinsons Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024)

9.4 Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size (2019-2030)

10.2 Middle East & Africa Alzheimers and Parkinsons Diseases Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024)

10.4 Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 Hoffmann-La Roche

11.1.1 Hoffmann-La Roche Company Detail

11.1.2 Hoffmann-La Roche Business Overview

11.1.3 Hoffmann-La Roche Alzheimers and Parkinsons Diseases Introduction

11.1.4 Hoffmann-La Roche Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.1.5 Hoffmann-La Roche Recent Development

11.2 Novartis

11.2.1 Novartis Company Detail

11.2.2 Novartis Business Overview

11.2.3 Novartis Alzheimers and Parkinsons Diseases Introduction

11.2.4 Novartis Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.2.5 Novartis Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Detail

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Alzheimers and Parkinsons Diseases Introduction

11.3.4 Pfizer Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.3.5 Pfizer Recent Development

11.4 Merck

11.4.1 Merck Company Detail

11.4.2 Merck Business Overview

11.4.3 Merck Alzheimers and Parkinsons Diseases Introduction

11.4.4 Merck Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.4.5 Merck Recent Development

11.5 Eli Lilly

11.5.1 Eli Lilly Company Detail

11.5.2 Eli Lilly Business Overview

11.5.3 Eli Lilly Alzheimers and Parkinsons Diseases Introduction

11.5.4 Eli Lilly Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.5.5 Eli Lilly Recent Development

11.6 Orion Pharma

11.6.1 Orion Pharma Company Detail

11.6.2 Orion Pharma Business Overview

11.6.3 Orion Pharma Alzheimers and Parkinsons Diseases Introduction

11.6.4 Orion Pharma Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.6.5 Orion Pharma Recent Development

11.7 UCB

11.7.1 UCB Company Detail

11.7.2 UCB Business Overview

11.7.3 UCB Alzheimers and Parkinsons Diseases Introduction

11.7.4 UCB Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.7.5 UCB Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Detail

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Alzheimers and Parkinsons Diseases Introduction

11.8.4 AstraZeneca Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.8.5 AstraZeneca Recent Development

11.9 Biogen

11.9.1 Biogen Company Detail

11.9.2 Biogen Business Overview

11.9.3 Biogen Alzheimers and Parkinsons Diseases Introduction

11.9.4 Biogen Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.9.5 Biogen Recent Development

11.10 Teva Pharmaceutical Industries

11.10.1 Teva Pharmaceutical Industries Company Detail

11.10.2 Teva Pharmaceutical Industries Business Overview

11.10.3 Teva Pharmaceutical Industries Alzheimers and Parkinsons Diseases Introduction

11.10.4 Teva Pharmaceutical Industries Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.10.5 Teva Pharmaceutical Industries Recent Development

11.11 AbbVie

11.11.1 AbbVie Company Detail

11.11.2 AbbVie Business Overview

11.11.3 AbbVie Alzheimers and Parkinsons Diseases Introduction

11.11.4 AbbVie Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.11.5 AbbVie Recent Development

11.12 Vertical Pharmaceuticals

11.12.1 Vertical Pharmaceuticals Company Detail

11.12.2 Vertical Pharmaceuticals Business Overview

11.12.3 Vertical Pharmaceuticals Alzheimers and Parkinsons Diseases Introduction

11.12.4 Vertical Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.12.5 Vertical Pharmaceuticals Recent Development

11.13 ALLERGAN

11.13.1 ALLERGAN Company Detail

11.13.2 ALLERGAN Business Overview

11.13.3 ALLERGAN Alzheimers and Parkinsons Diseases Introduction

11.13.4 ALLERGAN Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.13.5 ALLERGAN Recent Development

11.14 ACADIA Pharmaceuticals

11.14.1 ACADIA Pharmaceuticals Company Detail

11.14.2 ACADIA Pharmaceuticals Business Overview

11.14.3 ACADIA Pharmaceuticals Alzheimers and Parkinsons Diseases Introduction

11.14.4 ACADIA Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.14.5 ACADIA Pharmaceuticals Recent Development

11.15 Impax Laboratories

11.15.1 Impax Laboratories Company Detail

11.15.2 Impax Laboratories Business Overview

11.15.3 Impax Laboratories Alzheimers and Parkinsons Diseases Introduction

11.15.4 Impax Laboratories Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.15.5 Impax Laboratories Recent Development

11.16 GE healthcare

11.16.1 GE healthcare Company Detail

11.16.2 GE healthcare Business Overview

11.16.3 GE healthcare Alzheimers and Parkinsons Diseases Introduction

11.16.4 GE healthcare Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.16.5 GE healthcare Recent Development

11.17 VTV Therapeutics

11.17.1 VTV Therapeutics Company Detail

11.17.2 VTV Therapeutics Business Overview

11.17.3 VTV Therapeutics Alzheimers and Parkinsons Diseases Introduction

11.17.4 VTV Therapeutics Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024)

11.17.5 VTV Therapeutics Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Alzheimers and Parkinsons Diseases Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

    Table 2. Key Players of Alzheimers

    Table 3. Key Players of Parkinsons

    Table 4. Global Alzheimers and Parkinsons Diseases Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

    Table 5. Global Alzheimers and Parkinsons Diseases Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

    Table 6. Global Alzheimers and Parkinsons Diseases Market Size by Region (2019-2024) & (US$ Million)

    Table 7. Global Alzheimers and Parkinsons Diseases Market Share by Region (2019-2024)

    Table 8. Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Region (2025-2030) & (US$ Million)

    Table 9. Global Alzheimers and Parkinsons Diseases Market Share by Region (2025-2030)

    Table 10. Alzheimers and Parkinsons Diseases Market Trends

    Table 11. Alzheimers and Parkinsons Diseases Market Drivers

    Table 12. Alzheimers and Parkinsons Diseases Market Challenges

    Table 13. Alzheimers and Parkinsons Diseases Market Restraints

    Table 14. Global Alzheimers and Parkinsons Diseases Revenue by Players (2019-2024) & (US$ Million)

    Table 15. Global Alzheimers and Parkinsons Diseases Market Share by Players (2019-2024)

    Table 16. Global Top Alzheimers and Parkinsons Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alzheimers and Parkinsons Diseases as of 2023)

    Table 17. Ranking of Global Top Alzheimers and Parkinsons Diseases Companies by Revenue (US$ Million) in 2023

    Table 18. Global 5 Largest Players Market Share by Alzheimers and Parkinsons Diseases Revenue (CR5 and HHI) & (2019-2024)

    Table 19. Key Players Headquarters and Area Served

    Table 20. Key Players Alzheimers and Parkinsons Diseases Product Solution and Service

    Table 21. Date of Enter into Alzheimers and Parkinsons Diseases Market

    Table 22. Mergers & Acquisitions, Expansion Plans

    Table 23. Global Alzheimers and Parkinsons Diseases Market Size by Type (2019-2024) & (US$ Million)

    Table 24. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Type (2019-2024)

    Table 25. Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Type (2025-2030) & (US$ Million)

    Table 26. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Type (2025-2030)

    Table 27. Global Alzheimers and Parkinsons Diseases Market Size by Application (2019-2024) & (US$ Million)

    Table 28. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Application (2019-2024)

    Table 29. Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Application (2025-2030) & (US$ Million)

    Table 30. Global Alzheimers and Parkinsons Diseases Revenue Market Share by Application (2025-2030)

    Table 31. North America Alzheimers and Parkinsons Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 32. North America Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024) & (US$ Million)

    Table 33. North America Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030) & (US$ Million)

    Table 34. Europe Alzheimers and Parkinsons Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 35. Europe Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024) & (US$ Million)

    Table 36. Europe Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030) & (US$ Million)

    Table 37. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

    Table 38. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2019-2024) & (US$ Million)

    Table 39. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size by Region (2025-2030) & (US$ Million)

    Table 40. Latin America Alzheimers and Parkinsons Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 41. Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024) & (US$ Million)

    Table 42. Latin America Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030) & (US$ Million)

    Table 43. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

    Table 44. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2019-2024) & (US$ Million)

    Table 45. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size by Country (2025-2030) & (US$ Million)

    Table 46. Hoffmann-La Roche Company Detail

    Table 47. Hoffmann-La Roche Business Overview

    Table 48. Hoffmann-La Roche Alzheimers and Parkinsons Diseases Product

    Table 49. Hoffmann-La Roche Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 50. Hoffmann-La Roche Recent Development

    Table 51. Novartis Company Detail

    Table 52. Novartis Business Overview

    Table 53. Novartis Alzheimers and Parkinsons Diseases Product

    Table 54. Novartis Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 55. Novartis Recent Development

    Table 56. Pfizer Company Detail

    Table 57. Pfizer Business Overview

    Table 58. Pfizer Alzheimers and Parkinsons Diseases Product

    Table 59. Pfizer Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 60. Pfizer Recent Development

    Table 61. Merck Company Detail

    Table 62. Merck Business Overview

    Table 63. Merck Alzheimers and Parkinsons Diseases Product

    Table 64. Merck Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 65. Merck Recent Development

    Table 66. Eli Lilly Company Detail

    Table 67. Eli Lilly Business Overview

    Table 68. Eli Lilly Alzheimers and Parkinsons Diseases Product

    Table 69. Eli Lilly Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 70. Eli Lilly Recent Development

    Table 71. Orion Pharma Company Detail

    Table 72. Orion Pharma Business Overview

    Table 73. Orion Pharma Alzheimers and Parkinsons Diseases Product

    Table 74. Orion Pharma Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 75. Orion Pharma Recent Development

    Table 76. UCB Company Detail

    Table 77. UCB Business Overview

    Table 78. UCB Alzheimers and Parkinsons Diseases Product

    Table 79. UCB Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 80. UCB Recent Development

    Table 81. AstraZeneca Company Detail

    Table 82. AstraZeneca Business Overview

    Table 83. AstraZeneca Alzheimers and Parkinsons Diseases Product

    Table 84. AstraZeneca Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 85. AstraZeneca Recent Development

    Table 86. Biogen Company Detail

    Table 87. Biogen Business Overview

    Table 88. Biogen Alzheimers and Parkinsons Diseases Product

    Table 89. Biogen Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 90. Biogen Recent Development

    Table 91. Teva Pharmaceutical Industries Company Detail

    Table 92. Teva Pharmaceutical Industries Business Overview

    Table 93. Teva Pharmaceutical Industries Alzheimers and Parkinsons Diseases Product

    Table 94. Teva Pharmaceutical Industries Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 95. Teva Pharmaceutical Industries Recent Development

    Table 96. AbbVie Company Detail

    Table 97. AbbVie Business Overview

    Table 98. AbbVie Alzheimers and Parkinsons Diseases Product

    Table 99. AbbVie Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 100. AbbVie Recent Development

    Table 101. Vertical Pharmaceuticals Company Detail

    Table 102. Vertical Pharmaceuticals Business Overview

    Table 103. Vertical Pharmaceuticals Alzheimers and Parkinsons Diseases Product

    Table 104. Vertical Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 105. Vertical Pharmaceuticals Recent Development

    Table 106. ALLERGAN Company Detail

    Table 107. ALLERGAN Business Overview

    Table 108. ALLERGAN Alzheimers and Parkinsons Diseases Product

    Table 109. ALLERGAN Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 110. ALLERGAN Recent Development

    Table 111. ACADIA Pharmaceuticals Company Detail

    Table 112. ACADIA Pharmaceuticals Business Overview

    Table 113. ACADIA Pharmaceuticals Alzheimers and Parkinsons Diseases Product

    Table 114. ACADIA Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 115. ACADIA Pharmaceuticals Recent Development

    Table 116. Impax Laboratories Company Detail

    Table 117. Impax Laboratories Business Overview

    Table 118. Impax Laboratories Alzheimers and Parkinsons Diseases Product

    Table 119. Impax Laboratories Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 120. Impax Laboratories Recent Development

    Table 121. GE healthcare Company Detail

    Table 122. GE healthcare Business Overview

    Table 123. GE healthcare Alzheimers and Parkinsons Diseases Product

    Table 124. GE healthcare Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 125. GE healthcare Recent Development

    Table 126. VTV Therapeutics Company Detail

    Table 127. VTV Therapeutics Business Overview

    Table 128. VTV Therapeutics Alzheimers and Parkinsons Diseases Product

    Table 129. VTV Therapeutics Revenue in Alzheimers and Parkinsons Diseases Business (2019-2024) & (US$ Million)

    Table 130. VTV Therapeutics Recent Development

    Table 131. Research Programs/Design for This Report

    Table 132. Key Data Information from Secondary Sources

    Table 133. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Alzheimers and Parkinsons Diseases Market Size Comparison by Type (2024-2030) & (US$ Million)

    Figure 2. Global Alzheimers and Parkinsons Diseases Market Share by Type: 2023 VS 2030

    Figure 3. Alzheimers Features

    Figure 4. Parkinsons Features

    Figure 5. Global Alzheimers and Parkinsons Diseases Market Size Comparison by Application (2024-2030) & (US$ Million)

    Figure 6. Global Alzheimers and Parkinsons Diseases Market Share by Application: 2023 VS 2030

    Figure 7. Hospital Case Studies

    Figure 8. Clinic Case Studies

    Figure 9. Other Case Studies

    Figure 10. Alzheimers and Parkinsons Diseases Report Years Considered

    Figure 11. Global Alzheimers and Parkinsons Diseases Market Size (US$ Million), Year-over-Year: 2019-2030

    Figure 12. Global Alzheimers and Parkinsons Diseases Market Size, (US$ Million), 2019 VS 2023 VS 2030

    Figure 13. Global Alzheimers and Parkinsons Diseases Market Share by Region: 2023 VS 2030

    Figure 14. Global Alzheimers and Parkinsons Diseases Market Share by Players in 2023

    Figure 15. Global Top Alzheimers and Parkinsons Diseases Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Alzheimers and Parkinsons Diseases as of 2023)

    Figure 16. The Top 10 and 5 Players Market Share by Alzheimers and Parkinsons Diseases Revenue in 2023

    Figure 17. North America Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 18. North America Alzheimers and Parkinsons Diseases Market Share by Country (2019-2030)

    Figure 19. United States Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 20. Canada Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 21. Europe Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 22. Europe Alzheimers and Parkinsons Diseases Market Share by Country (2019-2030)

    Figure 23. Germany Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 24. France Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 25. U.K. Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 26. Italy Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 27. Russia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 28. Nordic Countries Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 29. Asia-Pacific Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 30. Asia-Pacific Alzheimers and Parkinsons Diseases Market Share by Region (2019-2030)

    Figure 31. China Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 32. Japan Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 33. South Korea Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 34. Southeast Asia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 35. India Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 36. Australia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 37. Latin America Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 38. Latin America Alzheimers and Parkinsons Diseases Market Share by Country (2019-2030)

    Figure 39. Mexico Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 40. Brazil Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 41. Middle East & Africa Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 42. Middle East & Africa Alzheimers and Parkinsons Diseases Market Share by Country (2019-2030)

    Figure 43. Turkey Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 44. Saudi Arabia Alzheimers and Parkinsons Diseases Market Size YoY Growth (2019-2030) & (US$ Million)

    Figure 45. Hoffmann-La Roche Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 46. Novartis Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 47. Pfizer Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 48. Merck Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 49. Eli Lilly Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 50. Orion Pharma Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 51. UCB Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 52. AstraZeneca Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 53. Biogen Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 54. Teva Pharmaceutical Industries Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 55. AbbVie Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 56. Vertical Pharmaceuticals Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 57. ALLERGAN Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 58. ACADIA Pharmaceuticals Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 59. Impax Laboratories Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 60. GE healthcare Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 61. VTV Therapeutics Revenue Growth Rate in Alzheimers and Parkinsons Diseases Business (2019-2024)

    Figure 62. Bottom-up and Top-down Approaches for This Report

    Figure 63. Data Triangulation

    Figure 64. Key Executives Interviewed